San Antonio Breast Cancer Symposium | Conference

Pembrolizumab Plus Radiation Yields Improvements in T-Cell Infiltration in Early Breast Cancer

December 11th 2025

Patients with early breast cancer who received pembrolizumab plus radiation therapy experienced significant improvements in T-Cell infiltration and promising pCR rates.

T-DXd Displays iDFS Benefit in Key Subgroups of HER2+ Early Breast Cancer With Residual Invasive Disease

December 11th 2025

T-DXd yielded iDFS improvements in HER2-positive early breast cancer with residual invasive disease, irrespective of HER2 expression of neoadjuvant chemotherapy type.

Maintenance Tucatinib Plus HP Extends Median PFS Beyond 2 Years in Advanced HER2+ Breast Cancer

December 11th 2025

Tucatinib plus HP improved median investigator-assessed PFS by 8.6 months as first-line maintenance vs HP alone in HER2-positive metastatic breast cancer.

Dr Alkassis on Cathepsin Protease Expression and Its OS Association With T-DXd in Metastatic Breast Cancer

December 11th 2025

Samer Alkassis, MD, PhD, discusses how cathepsin protease expression may correlate with survival outcomes to trastuzumab deruxtecan in metastatic breast cancer.

Trastuzumab Deruxtecan Plus Pertuzumab Does Not Worsen QOL in HER2+ Metastatic Breast Cancer

December 10th 2025

Frontline treatment with T-DXd plus pertuzumab improved QOL vs THP in patients with HER2-positive advanced or metastatic breast cancer.

Dr Hamilton on First-Line Tucatinib-Based Maintenance in HER2+ Metastatic Breast Cancer

December 10th 2025

Erika P. Hamilton, MD, discusses data from HER2CLIMB-05 evaluating tucatinib plus trastuzumab/pertuzumab first-line maintenance in HER2-positive breast cancer.

Sacituzumab Govitecan Maintains QOL Benefit Over Chemotherapy in Previously Untreated TNBC

December 10th 2025

PRO data from ASCENT-03 showed that the mean change in physical functioning from baseline to week 25 favored sacituzumab govitecan over chemotherapy.

Sacituzumab Govitecan Fails to Meet Primary PFS End Point in First-Line HR+/HER2– mBC

December 10th 2025

Sacituzumab govitecan did not improve PFS per BICR vs chemotherapy after endocrine therapy in hormone-receptor–positive/HER2-negative breast cancer.

Abemaciclib Monotherapy Shows Efficacy After CDK4/6 Inhibition in HR+/HER2– Breast Cancer

December 10th 2025

Abemaciclib monotherapy displayed a clinical benefit in some patients with HR+/HER2– breast cancer after CDK4/6 inhibitor therapy.

Multimodal AI Model Prognostic for Long-Term Recurrence Following Treatment for Early Breast Cancer

December 10th 2025

The multimodal ICM+ model was prognostic for long-term recurrence following treatment in early breast cancer.

Giredestrant Improves iDFS Compared With Endocrine Therapy in ER+, HER2– Breast Cancer

December 10th 2025

Giredestrant improved invasive disease-free survival vs endocrine therapy in ER-positive, HER2-negative, medium- and high-risk early breast cancer.

Adjuvant Aromatase Inhibition Is Associated With Improved DFS, TTDR in HR+/HER2+ Breast Cancer

December 10th 2025

Adjuvant AI therapy improved DFS and TTDR vs a SERM in patients with hormone receptor–positive, HER2-positive early breast cancer.

Dr Rimm on Conceptual Considerations Surrounding ADC Mechanisms in Breast Cancer

December 10th 2025

David Rimm, MD, PhD, discusses key conceptual considerations and discrepancies regarding the mechanisms of action of ADCs in breast cancer treatment.

Dr Vincent-Salomon on Persisting Gaps in Clinical Interpretation of Invasive Lobular Carcinoma

December 9th 2025

Anne Vincent-Salomon, PR, MD, PhD, HDR, highlights persistent gaps that continue to challenge reproducibility and clinical interpretation in the diagnostic classification of invasive lobular carcinoma.

Experts Highlight HR+ and TNBC Trials to Watch Ahead of SABCS 2025

December 8th 2025

Leading clinicians preview anticipated HR+ and TNBC studies at SABCS 2025.

Experts Preview Anticipated HER2-Positive Breast Cancer Data Ahead of SABCS 2025

December 4th 2025

Leading experts highlight key HER2-positive studies ahead of SABCS 2025.

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

December 17th 2024

Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care.

Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer

December 16th 2024

Radiation therapy produced superior HRQOL outcomes and fewer toxicities vs endocrine therapy in older patients with stage I luminal-like breast cancer.

Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer

December 16th 2024

Ultra-sensitive tissue-free ctDNA testing showed that baseline ctDNA was associated with larger pathological tumor size in HR-positive breast cancer.

Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer

December 15th 2024

Elacestrant increased real-world TTNT for patients with ESR1-mutant HR-positive/HER2-negative breast cancer vs PFS from the phase 3 EMERALD trial.